2022
Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein L, Saliba W. Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis. Clinical Infectious Diseases 2022, 76: 453-460. PMID: 36130189, DOI: 10.1093/cid/ciac781.Peer-Reviewed Original ResearchConceptsSevere COVID-19Composite outcomeSevere acute respiratory syndrome coronavirus 2COVID-19-specific mortalityModerate coronavirus disease 2019Acute respiratory syndrome coronavirus 2Propensity Score Matched AnalysisCOVID-19-related mortalityCOVID-19Respiratory syndrome coronavirus 2High-risk patientsTreatment of mildSyndrome coronavirus 2Emergency use authorizationCoronavirus disease 2019Largest healthcare providerHazard ratioVaccination statusMatched AnalysisCoronavirus 2Subgroup analysisDisease 2019High riskPositive testPatientsCognitive dysfunction following COVID-19 infection
Hadad R, Khoury J, Stanger C, Fisher T, Schneer S, Ben-Hayun R, Possin K, Valcour V, Aharon-Peretz J, Adir Y. Cognitive dysfunction following COVID-19 infection. Journal Of NeuroVirology 2022, 28: 430-437. PMID: 35618983, PMCID: PMC9134977, DOI: 10.1007/s13365-022-01079-y.Peer-Reviewed Original ResearchConceptsDisease severityPulmonary function testsDetailed medical historyLong-term sequelaeCOVID-19 infectionTotal MoCA scoreMontreal Cognitive AssessmentNormal laboratory testsCognitive performancePhonemic fluencyExecutive functionAge 49.5Neurologic consultationNeurological examinationBrain CTFunction testsNeurological consultationHealthy patientsNeurologic syndromeCOVID clinicMedical historyPremorbid conditionsCognitive dysfunctionMoCA scoresMoCA test
2021
Point Shear Wave Elastography for Assessing Liver Stiffness in Chronic Liver Diseases of Different Etiologies Compared to Biopsy.
Saadi T, Khoury J, Toukan W, Krimasky R, Veitsman E, Baruch Y, Gaitini D, Beck-Razi N. Point Shear Wave Elastography for Assessing Liver Stiffness in Chronic Liver Diseases of Different Etiologies Compared to Biopsy. Israel Medical Association Journal 2021, 23: 223-228. PMID: 33899354.Peer-Reviewed Original ResearchConceptsChronic liver diseaseLiver diseaseLiver stiffnessDifferent etiologiesControl groupViral hepatitisLiver biopsyBiopsy resultsFibrosis degreeStudy groupMedian stiffnessShear wave elastographyHealthy adultsProspective single-center studyNon-significant fibrosisNon-viral hepatitisSingle-center studyLiver biopsy resultsMETAVIR scoring systemPoint shear wave elastographyPSWE measurementsAdult patientsSubgroup analysisLiver fibrosisHealthy controls
2020
SOFA score and short-term mortality in acute decompensated heart failure
Elias A, Agbarieh R, Saliba W, Khoury J, Bahouth F, Nashashibi J, Azzam Z. SOFA score and short-term mortality in acute decompensated heart failure. Scientific Reports 2020, 10: 20802. PMID: 33257739, PMCID: PMC7705654, DOI: 10.1038/s41598-020-77967-2.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureSequential Organ Function Assessment (SOFA) scoreShort-term mortalityDecompensated heart failureSOFA scoreHigh-risk patientsHospital mortalityRisk patientsHeart failureLife-threatening conditionCurve (AUC) of receiverFirst hospitalizationPrimary diagnosisRisk scorePatientsMortalityAssessment scoresStrict monitoringExcellent scoresCharacteristic curveHospitalizationScoresGood predictive accuracyProper managementSepsisHistomorphometric Findings May Help Predicting Response in Patients with Chronic Liver Disease.
Abu Raya M, Klein A, Sabo E, Yaccob A, Baruch Y, Khoury J, Saadi T. Histomorphometric Findings May Help Predicting Response in Patients with Chronic Liver Disease. Israel Medical Association Journal 2020, 22: 320-325. PMID: 32378826.Peer-Reviewed Original ResearchConceptsHepatitis C virusViral responseInflammatory cellsChronic hepatitis C virusChronic HCV infectionChronic liver diseaseEra of treatmentLiver needle biopsyNon-SVRHCV infectionCollagen fibersLiver unitPeg-interferonLiver diseaseHistological findingsC virusHistomorphometric findingsLeading causeNeedle biopsyHistological variablesPatient responseLiver architectureTreatment responseHepatocellular carcinomaPrevious patients
2019
Clinical characteristics and outcomes of patients with Escherichia coli in airway samples
Schneer S, Khoury J, Adir Y, Stein N, Mishan P, Ken‐Dror S, Weber G, Meler R, Khateeb A, Shteinberg M. Clinical characteristics and outcomes of patients with Escherichia coli in airway samples. The Clinical Respiratory Journal 2019, 14: 205-213. PMID: 31799802, DOI: 10.1111/crj.13116.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Bacterial AgentsBronchiectasisCase-Control StudiesCommunity-Acquired InfectionsCross InfectionCystic FibrosisDrug Resistance, BacterialEscherichia coliEscherichia coli InfectionsFemaleHospitalizationHumansMaleMicrobial Sensitivity TestsMiddle AgedRespiratory Tract InfectionsSputumConceptsRespiratory secretionsResistant E. coliE. coli positive culturesResistant strainsMore hospitalization daysOutcomes of patientsGroup of patientsCommunity-acquired infectionsClinical characteristicsHospital daysPulmonary infectionHospitalization daysAmbulatory patientsPrevious hospitalizationAirway samplesPrognostic valueRespiratory pathogensCommon pathogensPositive culturesPatientsNosocomial pathogenAntibiotic classesAntimicrobial classesSecretionElevated mortalityExtrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection
Khoury J, Nassar G, Kramsky R, Saadi T. Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection. Journal Of Gastrointestinal Cancer 2019, 51: 584-590. PMID: 31407252, DOI: 10.1007/s12029-019-00293-y.Peer-Reviewed Original ResearchConceptsHepatitis C virusExtrahepatic malignanciesAntiviral agentsParitaprevir/ritonavir/ombitasvirChronic hepatitis C virusRecurrent metastatic breast cancerRecurrent transitional cell carcinomaMethodsFour hundred thirtyChronic HCV infectionDirect antiviral agentsMetastatic breast cancerTreatment of choiceTransitional cell carcinomaPossible relationshipDAA treatmentResultsNine patientsHCV infectionCommon regimenCell carcinomaC virusLaryngeal carcinomaPancreatic adenocarcinomaLung carcinomaBreast cancerUrinary bladderBlood urea nitrogen variation upon admission and at discharge in patients with heart failure
Khoury J, Bahouth F, Stabholz Y, Elias A, Mashiach T, Aronson D, Azzam Z. Blood urea nitrogen variation upon admission and at discharge in patients with heart failure. ESC Heart Failure 2019, 6: 809-816. PMID: 31199082, PMCID: PMC6676277, DOI: 10.1002/ehf2.12471.Peer-Reviewed Original ResearchConceptsBlood urea nitrogenDay mortality rateHeart failureHigher BUN levelsPrognostic predictorBUN levelsMortality rateAcute decompensated heart failureDecompensated heart failureLong-term mortalityBrain natriuretic peptideGlomerular filtration rateShort-term mortalityLack of improvementBUN changeDay mortalityHospital stayCreatinine levelsFirst hospitalizationFirst admissionWorse prognosisMean ageNatriuretic peptidePrognostic valueRetrospective studyThe association between fluconazole dose and MIC with mortality and persistence in candidemia
Ghanem-Zoubi N, Qasum M, Khoury J, Zorbavel D, Arnon M, Geffen Y, Paul M. The association between fluconazole dose and MIC with mortality and persistence in candidemia. European Journal Of Clinical Microbiology & Infectious Diseases 2019, 38: 1773-1780. PMID: 31197619, DOI: 10.1007/s10096-019-03611-1.Peer-Reviewed Original ResearchConceptsAUC24/MICClinical outcomesC. glabrata candidemiaComposite of mortalityExposure parametersLowest MIC valueSimilar non-significant differencesFluconazole doseFluconazole dosingPersistent candidemiaSingle centerMIC valuesClinical failureInclusion criteriaCandidemiaPatientsDay 14Non-significant differenceHigh MICsFluconazole MICsStudy periodMortalityCandida speciesMICC. glabrataRisk Factors for Non-Albicans Candidemia Focusing on Prior Antifungal and Immunosuppressive Therapy.
Ghanem-Zoubi N, Khoury J, Arnon M, Zorbavel D, Geffen Y, Paul M. Risk Factors for Non-Albicans Candidemia Focusing on Prior Antifungal and Immunosuppressive Therapy. Israel Medical Association Journal 2019, 21: 303-307. PMID: 31140219.Peer-Reviewed Original ResearchConceptsBlood stream infectionsSignificant risk factorsRisk factorsImmunosuppression therapyImmunosuppressive therapySignificant independent risk factorsRambam Health Care CampusCandida blood stream infectionEpisodes of candidemiaRetrospective cohort studyIndependent risk factorTertiary medical centerSubgroup of patientsBone marrow transplantationHealth Care CampusNon-albicans candidemiaNAC candidemiaNAC sppAdult patientsCohort studyMarrow transplantationClinical manifestationsMedical CenterCandidemiaPatients
2018
The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study
Ghanem-Zoubi N, Zorbavel D, Khoury J, Geffen Y, Qasum M, Predescu S, Paul M. The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study. European Journal Of Clinical Microbiology & Infectious Diseases 2018, 37: 2397-2404. PMID: 30284179, DOI: 10.1007/s10096-018-3389-1.Peer-Reviewed Original ResearchConceptsCLSI 2012Appropriate antifungal treatmentDefinitive treatmentOdds ratioAntifungal treatmentAntimicrobial Susceptibility Testing (EUCAST) breakpointsAppropriate definitive treatmentRetrospective observational studyAdjusted odds ratioAppropriate empirical treatmentBivariate logistic regressionCandidemia onsetCandidemia episodesEmpiric treatmentTreatment appropriatenessTertiary centerRetrospective studyCLSI breakpointsEmpirical treatmentObservational studyBreakpoint definitionPatientsResistance prevalenceMortalityLogistic regressionIs There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies?
Saadi T, Khoury J. Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies? Journal Of Clinical Gastroenterology 2018, 52: 353-359. PMID: 28590324, DOI: 10.1097/mcg.0000000000000853.Peer-Reviewed Original ResearchConceptsDirect antiviral agentsAdverse eventsHepatocellular carcinomaAntiviral agentsChronic hepatitis C virus (HCV) infectionParitaprevir/ritonavir/ombitasvirHepatitis C virus infectionDe novo hepatocellular carcinomaLarge clinical trial dataSerum HCV RNAC virus infectionNovo hepatocellular carcinomaTreatment of choiceTransitional cell carcinomaAggressive hepatocellular carcinomaAggressive transitional cell carcinomaClinical trial dataDevelopment of malignancyHCV infectionHCV RNAHCV genotypesLiver diseaseCell carcinomaLaryngeal carcinomaPancreatic adenocarcinomaGlycogenic hepatopathy
Khoury J, Zohar Y, Shehadeh N, Saadi T. Glycogenic hepatopathy. Hepatobiliary & Pancreatic Diseases International 2018, 17: 113-118. PMID: 29709217, DOI: 10.1016/j.hbpd.2018.02.006.Peer-Reviewed Original ResearchConceptsGlycogenic hepatopathyLiver biopsyLiver diseaseRight upper quadrant abdominal painUpper quadrant abdominal painEnd-stage liver diseaseNonalcoholic fatty liver diseaseUncontrolled diabetes mellitusQuadrant abdominal painFatty liver diseaseRoutine blood testsTight glycemic controlLiver glycogen accumulationPubMed database searchAbdominal painClinical responseElevated liverDiabetes mellitusGlycemic controlClinical presentationBlood testsPhysical examinationMedical historyNoninvasive testsLiver enzymes
2017
Duration of viral shedding and factors associated with prolonged shedding among inpatients with influenza treated with oseltamivir: a prospective cohort study
Khoury J, Szwarcwort M, Kra-oz Z, Saffuri M, Seh K, Yahalomi T, Braun E, Azzam Z, Paul M, Neuberger A. Duration of viral shedding and factors associated with prolonged shedding among inpatients with influenza treated with oseltamivir: a prospective cohort study. European Journal Of Clinical Microbiology & Infectious Diseases 2017, 37: 319-323. PMID: 29143145, DOI: 10.1007/s10096-017-3135-0.Peer-Reviewed Original ResearchConceptsRisk factorsBlood pressureDiagnostic yieldDay 2Lower diastolic blood pressureNegative PCR testIndependent risk factorProspective cohort studyProspective observational studyDiastolic blood pressureLower blood pressurePCR testInitiation of treatmentLow diagnostic yieldFirst positive testEvaluable patientsInfluenza PCROseltamivir administrationOseltamivir treatmentCohort studyMedian ageAdult inpatientsViral sheddingPositive PCRPCR positivitySecondary antibiotic resistance of Helicobacter pylori isolates in Israeli children and adults
Khoury J, Geffen Y, Shaul R, Sholy H, Chowers Y, Saadi T. Secondary antibiotic resistance of Helicobacter pylori isolates in Israeli children and adults. Journal Of Global Antimicrobial Resistance 2017, 10: 182-185. PMID: 28732784, DOI: 10.1016/j.jgar.2017.05.017.Peer-Reviewed Original ResearchConceptsH. pylori culturePositive H. pylori culturePylori cultureTherapeutic regimensH. pyloriRambam Health Care CampusSecondary antibiotic resistanceHelicobacter pylori infectionHealth Care CampusAntibiotic resistanceH. pylori strainsHelicobacter pylori isolatesStandard therapyPylori infectionGastric biopsiesSecondary antimicrobial resistanceLEV resistancePylori isolatesPatientsAntimicrobial susceptibilityClarithromycinPylori strainsMetronidazoleAmoxicillinAntimicrobial resistanceThe prognostic value of brain natriuretic peptide (BNP) in non-cardiac patients with sepsis, ultra-long follow-up
Khoury J, Arow M, Elias A, Makhoul B, Berger G, Kaplan M, Mashiach T, Ismael-Badarneh R, Aronson D, Azzam Z. The prognostic value of brain natriuretic peptide (BNP) in non-cardiac patients with sepsis, ultra-long follow-up. Journal Of Critical Care 2017, 42: 117-122. PMID: 28719839, DOI: 10.1016/j.jcrc.2017.07.009.Peer-Reviewed Original ResearchConceptsBrain natriuretic peptideLong-term mortalityBNP levelsElevated brain natriuretic peptide levelsRole of BNPBrain natriuretic peptide levelsOrgan Failure Assessment scoreNatriuretic peptide levelsNon-cardiac patientsStrong independent predictorIncidence of morbidityLow-risk groupLong-term survivalMultivariate analysis modelHospital mortalityIndex hospitalizationCritical illnessHeart failureIndependent predictorsSeptic shockNatriuretic peptideOutcome predictorsPrognostic predictorPrognostic valueMultifactorial syndrome
2016
Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection
Saadi T, Khoury J. Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection. Journal Of Clinical Gastroenterology 2016, 50: 799. PMID: 27380458, DOI: 10.1097/mcg.0000000000000587.Commentaries, Editorials and LettersMeSH Keywords2-NaphthylamineAlanine TransaminaseAnilidesAntiviral AgentsAspartate AminotransferasesCarbamatesCyclopropanesDrug Therapy, CombinationFemaleHepatitis C, ChronicHumansLactams, MacrocyclicMacrocyclic CompoundsMiddle AgedProlineRibavirinRitonavirSulfonamidesUracilValineWithholding TreatmentPros and cons of circumcision: an evidence-based overview
Friedman B, Khoury J, Petersiel N, Yahalomi T, Paul M, Neuberger A. Pros and cons of circumcision: an evidence-based overview. Clinical Microbiology And Infection 2016, 22: 768-774. PMID: 27497811, DOI: 10.1016/j.cmi.2016.07.030.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHuman immunodeficiency virusRisk of infectionHigh human immunodeficiency virusSatisfaction of menRisk-benefit ratioHigh-quality evidenceInsertive anal intercourseEvidence-based overviewCons of circumcisionLack of harmHIV acquisitionSerious complicationsImmunodeficiency virusSexual functionSTI riskAdult circumcisionHigh prevalenceProtective effectAnal intercourseSterile settingsSmall studyMale partnersCircumcisionInfectionConflicting results
2014
Alkaline phosphatase level change in patients with osteosarcoma: its role as a predictive factor of tumor necrosis and clinical outcome.
Khoury J, Ben-Arush M, Weintraub M, Waldman E, Futerman B, Vlodavsky E, Postovsky S. Alkaline phosphatase level change in patients with osteosarcoma: its role as a predictive factor of tumor necrosis and clinical outcome. Israel Medical Association Journal 2014, 16: 26-32. PMID: 24575501.Peer-Reviewed Original ResearchConceptsTumor necrosisBetter prognosisClinical outcomesPredictive factorsHistological responseBetter survivalSerum alkaline phosphatase levelsEvidence of diseaseSignificant predictive factorsAlkaline phosphatase levelsNeoadjuvant chemotherapyOverall survivalWorse survivalFemale patientsMedical filesOsteosarcoma patientsPatientsPhosphatase levelsSAP responseNecrosisFirst monthRespondersPredictive indicatorDiseaseSurvival